To the Editor: Denosumab, a receptor activator of nuclear factor κ-B (RANK) ligand inhibitor, is now considered first-line therapy to prevent skeletal-related events in patients with bone metastases secondary to breast cancer and castration-resistant prostate cancer.1,2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Responses are now closed for this article.
We thank the patient for allowing us to report this case.
No relevant disclosures.